標題: Titlebook: Competition Law and Policy in the Japanese Pharmaceutical Sector; Akira Negishi,Masako Wakui,Naoko Mariyama Book 2022 The Editor(s) (if ap [打印本頁] 作者: Opulent 時間: 2025-3-21 17:34
書目名稱Competition Law and Policy in the Japanese Pharmaceutical Sector影響因子(影響力)
書目名稱Competition Law and Policy in the Japanese Pharmaceutical Sector影響因子(影響力)學科排名
書目名稱Competition Law and Policy in the Japanese Pharmaceutical Sector網(wǎng)絡(luò)公開度
書目名稱Competition Law and Policy in the Japanese Pharmaceutical Sector網(wǎng)絡(luò)公開度學科排名
書目名稱Competition Law and Policy in the Japanese Pharmaceutical Sector被引頻次
書目名稱Competition Law and Policy in the Japanese Pharmaceutical Sector被引頻次學科排名
書目名稱Competition Law and Policy in the Japanese Pharmaceutical Sector年度引用
書目名稱Competition Law and Policy in the Japanese Pharmaceutical Sector年度引用學科排名
書目名稱Competition Law and Policy in the Japanese Pharmaceutical Sector讀者反饋
書目名稱Competition Law and Policy in the Japanese Pharmaceutical Sector讀者反饋學科排名
作者: 肌肉 時間: 2025-3-21 21:57 作者: 明智的人 時間: 2025-3-22 03:16
Competition and Cooperation: Building a Sustainable Healthcare Delivery System in a Society with a Dompetition policy. It then reviews the challenges the system faces. The chapter concludes by discussing the issues to be considered further when creating a sustainable healthcare delivery system and enacting competition policies.作者: 租約 時間: 2025-3-22 07:00
Drug Regulation in Japan held liable arises. A remedial system for health damage caused by the proper use of medicinal products also exists. Although remedies are not limited to damage caused by unknown side effects, a certain set of requirements, different from that for civil liability, must be met to for the plaintiff to作者: cataract 時間: 2025-3-22 09:42 作者: 發(fā)誓放棄 時間: 2025-3-22 14:05 作者: 發(fā)誓放棄 時間: 2025-3-22 19:45 作者: VICT 時間: 2025-3-22 23:07 作者: 有斑點 時間: 2025-3-23 01:47 作者: OTHER 時間: 2025-3-23 06:11
2524-504X cal regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States...Japan is one of the biggest pharmaceutical markets in978-981-16-7816-5978-981-16-7814-1Series ISSN 2524-504X Series E-ISSN 2524-5058 作者: 修飾 時間: 2025-3-23 12:57
Abhinit Nagar,Jonathan A. Hartonibutors in the Japanese pharmaceutical sector. This chapter outlines the laws and regulations that shape how pharmaceutical markets operate in Japan and describes how these relevant rules interact. It also explores the major challenges the Japanese pharmaceutical industry faces.作者: indignant 時間: 2025-3-23 17:26
Natasha S. Barteneva,Ivan A. Vorobjevompetition policy. It then reviews the challenges the system faces. The chapter concludes by discussing the issues to be considered further when creating a sustainable healthcare delivery system and enacting competition policies.作者: Blood-Vessels 時間: 2025-3-23 18:15
Natasha S. Barteneva,Ivan A. Vorobjev held liable arises. A remedial system for health damage caused by the proper use of medicinal products also exists. Although remedies are not limited to damage caused by unknown side effects, a certain set of requirements, different from that for civil liability, must be met to for the plaintiff to作者: 注意力集中 時間: 2025-3-23 23:38
Abhinit Nagar,Jonathan A. Hartony in a cease-and-desist order. The detailed rules set out in the Fair Competition Code are rarely enforced by the industry’s self-regulatory body, which issues only a warning and guidance to violators. Disclosure, rather than prohibition, has become the primary way to control pharmaceutical companie作者: Debate 時間: 2025-3-24 06:07
https://doi.org/10.1007/978-1-4899-1552-8 Insurance Price List, which determines not only the cost, but also the medicines that can be used for treatment under the universal health insurance system. The MHLW also issues administrative guidance. As such, the pharmaceutical sector is heavily regulated. Despite such regulations, intense compe作者: 壯觀的游行 時間: 2025-3-24 09:09 作者: 四指套 時間: 2025-3-24 10:39 作者: 去掉 時間: 2025-3-24 15:21 作者: 有權(quán) 時間: 2025-3-24 19:29
Book 2022k also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States...Japan is one of the biggest pharmaceutical markets in作者: 嚴厲批評 時間: 2025-3-24 23:11
2524-504X eutical sector, including competition, intellectual property.This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including econo作者: blister 時間: 2025-3-25 06:04 作者: motor-unit 時間: 2025-3-25 09:09
https://doi.org/10.1007/978-1-4612-4430-1power over a patented technology or product. This result indicates that no challenge clauses should only be illegal when both preconditions are met. The Japan Fair Trade Commission’s approach to these clauses is largely consistent with these important theoretical insights.作者: Petechiae 時間: 2025-3-25 15:28 作者: 率直 時間: 2025-3-25 19:33
Vikash Gupta,Gautam Prasad,Paul Thompsonto adapt to these systemic changes. In the second half of the chapter, I describe the contributions of science to innovation in drug discovery and the relationship between patent protection and competition in the pharmaceutical industry, based on case studies of the development of 14 drugs created by Japanese pharmaceutical companies.作者: 高歌 時間: 2025-3-25 21:52 作者: cancellous-bone 時間: 2025-3-26 00:53
No Challenge Clauses in the Pharmaceutical Industry in Japanpower over a patented technology or product. This result indicates that no challenge clauses should only be illegal when both preconditions are met. The Japan Fair Trade Commission’s approach to these clauses is largely consistent with these important theoretical insights.作者: 懲罰 時間: 2025-3-26 04:47 作者: 正論 時間: 2025-3-26 09:03 作者: 大約冬季 時間: 2025-3-26 15:56 作者: Regurgitation 時間: 2025-3-26 16:49
Imaging Flow Cytometry of Multi-Nuclearitytional Health Insurance (NHI) drug price standard, the official price list for medicines in Japan. In this way, the patent system and the pharmaceutical regulations work together to provide incentives to create pharmaceuticals.作者: 玉米 時間: 2025-3-26 22:42
Collaboration Between the Patent System and Pharmaceutical Regulations for Drug-Discovery Innovationtional Health Insurance (NHI) drug price standard, the official price list for medicines in Japan. In this way, the patent system and the pharmaceutical regulations work together to provide incentives to create pharmaceuticals.作者: 半圓鑿 時間: 2025-3-27 01:29 作者: 持久 時間: 2025-3-27 05:23 作者: 臨時抱佛腳 時間: 2025-3-27 12:19 作者: sacrum 時間: 2025-3-27 14:37 作者: maladorit 時間: 2025-3-27 18:42
Natasha S. Barteneva,Ivan A. Vorobjevvelopment (R&D) and create new businesses are set out in the Health and Medical Care Strategy Promotion Act. The rules regulating medical research are established based on the Declaration of Helsinki. Additionally, the Clinical Research Act and other legal rules exist to ensure citizens’ trust in cl作者: 蛙鳴聲 時間: 2025-3-28 00:30
Imaging Flow Cytometry of Multi-Nuclearitytection) are crucial to dominating the competition in drug development. Monopolisation of pharmaceuticals is enforceable by Japanese patent and pharmaceutical regulations. Pharmaceutical regulations partly define the scope and duration of patent rights. On the other hand, they themselves are a means作者: AMPLE 時間: 2025-3-28 02:27
Abhinit Nagar,Jonathan A. Hartonents’ recovery, but also cause excessive medication use, increase medical costs and undermine merit-based competition amongst pharmaceutical companies, causing severe inefficiency in society. Japan’s regulatory approach towards pharmaceutical companies’ gift-giving practices is lenient and ineffecti作者: Consensus 時間: 2025-3-28 09:56 作者: Blasphemy 時間: 2025-3-28 12:22
https://doi.org/10.1007/978-1-4899-1552-8 The application of the AMA to horizontal agreements between businesses is concentrated on hard-core cartels such as price agreements made between competitors. The manufacture and sale of pharmaceuticals are regulated by the government. Yet alliances between pharmaceutical companies related to resea作者: Blatant 時間: 2025-3-28 17:20
https://doi.org/10.1007/978-3-030-59088-8ch year. These usually include at least one case from the pharmaceutical industry. This chapter reviews cases where the JFTC seems to have conducted a characteristic analysis. For example, the JFTC usually delineates a product market starting with the ATC (Anatomical Therapeutic Chemical Classificat作者: 最低點 時間: 2025-3-28 22:31 作者: Asparagus 時間: 2025-3-29 00:02 作者: evasive 時間: 2025-3-29 06:33
Propagation of Electromagnetic Waves,ory authorities consider competition impacts in addition to post-regulation by the competition authorities. In Japan, it is pre-regulated by the Ministry of Health, Labour and Welfare (MHLW) and the Central Social Insurance Medical Council (CSIMC), which consider competition at the point of drug pri作者: guardianship 時間: 2025-3-29 10:19
Vikash Gupta,Gautam Prasad,Paul Thompsonoverview of the history, which, like that of other industries, is one that is catching up with Western countries. After World War II, foreign products were introduced in Japan; thereafter, the country’s firms endeavoured to independently develop products, gradually improving drug discovery technolog作者: Lacunar-Stroke 時間: 2025-3-29 14:13 作者: 委屈 時間: 2025-3-29 15:55 作者: Hyperalgesia 時間: 2025-3-29 20:37
978-981-16-7816-5The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapor作者: 未成熟 時間: 2025-3-30 00:25 作者: 佛刊 時間: 2025-3-30 04:18
Regulation and Competition in the Pharmaceutical Industry in JapanMedical Devices (PMD Act) and the Health Insurance Act. These laws are administrated by the Ministry of Health, Labour and Welfare (MHLW), which regulates the entire process from entry into the market to the pricing and distribution of products. The necessity and reasonableness of such regulations h作者: glacial 時間: 2025-3-30 11:46
Competition and Cooperation: Building a Sustainable Healthcare Delivery System in a Society with a D regulatory reforms in the healthcare delivery system, including the introduction of collaboration promotion policies. The urgent demand for medical care that arose in 2020 to cope with the COVID-19 pandemic further demonstrates the necessity of a sustainable healthcare delivery system. This require作者: nitroglycerin 時間: 2025-3-30 14:19
Drug Regulation in Japanvelopment (R&D) and create new businesses are set out in the Health and Medical Care Strategy Promotion Act. The rules regulating medical research are established based on the Declaration of Helsinki. Additionally, the Clinical Research Act and other legal rules exist to ensure citizens’ trust in cl作者: intuition 時間: 2025-3-30 20:27
Collaboration Between the Patent System and Pharmaceutical Regulations for Drug-Discovery Innovationtection) are crucial to dominating the competition in drug development. Monopolisation of pharmaceuticals is enforceable by Japanese patent and pharmaceutical regulations. Pharmaceutical regulations partly define the scope and duration of patent rights. On the other hand, they themselves are a means
